{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:46:00Z","timestamp":1793418360465,"version":"4.5.0"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["NCIP01 CA117969"],"award-info":[{"award-number":["NCIP01 CA117969"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-75960-3","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T09:44:55Z","timestamp":1785145495000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Krishnan K.","family":"Mahadevan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana S.","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingrui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron A.","family":"Bickert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Kacperczyk-Perdyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyasee V.","family":"Kumbhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8976-540X","authenticated-orcid":false,"given":"Sujan","family":"Piya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amari M.","family":"Sockwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami J.","family":"Morse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent","family":"Arian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4743-3706","authenticated-orcid":false,"given":"Shabnam","family":"Shalapour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8721-1609","authenticated-orcid":false,"given":"David S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3166-8922","authenticated-orcid":false,"given":"Timothy P.","family":"Heffernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anirban","family":"Maitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2190-547X","authenticated-orcid":false,"given":"Raghu","family":"Kalluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"75960_CR1","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin, J. et al. Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor. Nat. Med. 28, 2171\u20132182 (2022).","journal-title":"Nat. Med."},{"key":"75960_CR2","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1158\/2767-9764.CRC-23-0222","volume":"3","author":"Kazi","year":"2023","unstructured":"Kazi. et al. Discovery of KRB-456, a KRAS G12D Switch-I\/II allosteric pocket binder that inhibits the growth of pancreatic cancer patient-derived tumors. Cancer Res. Commun. 3, 2623\u20132639 (2023).","journal-title":"Cancer Res. Commun."},{"key":"75960_CR3","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","volume":"65","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Identification of MRTX1133, a noncovalent, potent, and selective KRAS(G12D) inhibitor. J. Med. Chem. 65, 3123\u20133133 (2022).","journal-title":"J. Med. Chem."},{"key":"75960_CR4","doi-asserted-by":"crossref","unstructured":"Park, W. et al. 608O Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC). Annals of Oncology 35, S486\u2013S487 (2024).","DOI":"10.1016\/j.annonc.2024.08.675"},{"key":"75960_CR5","doi-asserted-by":"crossref","unstructured":"Spira, A. I. et al. Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors. J. Clin. Oncol. 43, 724\u2013724 (2025).","DOI":"10.1200\/JCO.2025.43.4_suppl.724"},{"key":"75960_CR6","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong, D. S. et al. KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors. N. Engl. J. Med. 383, 1207\u20131217 (2020).","journal-title":"N. Engl. J. Med."},{"key":"75960_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","volume":"63","author":"BA Lanman","year":"2020","unstructured":"Lanman, B. A. et al. Discovery of a Covalent Inhibitor of KRAS(G12C) (AMG 510) for the Treatment of Solid Tumors. J. Med. Chem. 63, 52\u201365 (2020).","journal-title":"J. Med. Chem."},{"key":"75960_CR8","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548\u2013551 (2013).","journal-title":"Nature"},{"key":"75960_CR9","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1021\/acsmedchemlett.8b00382","volume":"9","author":"JB Fell","year":"2018","unstructured":"Fell, J. B. et al. Discovery of tetrahydropyridopyrimidines as irreversible covalent inhibitors of KRAS-G12C with in vivo activity. ACS Med. Chem. Lett. 9, 1230\u20131234 (2018).","journal-title":"ACS Med. Chem. Lett."},{"key":"75960_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","volume":"10","author":"J Hallin","year":"2020","unstructured":"Hallin, J. et al. The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients. Cancer Discov. 10, 54\u201371 (2020).","journal-title":"Cancer Discov."},{"key":"75960_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA Janne","year":"2022","unstructured":"Janne, P. A. et al. Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation. N. Engl. J. Med. 387, 120\u2013131 (2022).","journal-title":"N. Engl. J. Med."},{"key":"75960_CR12","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","volume":"14","author":"J Jiang","year":"2024","unstructured":"Jiang, J. et al. Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. Cancer Discov. 14, 994\u20131017 (2024).","journal-title":"Cancer Discov."},{"key":"75960_CR13","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41586-024-07379-z","volume":"629","author":"UN Wasko","year":"2024","unstructured":"Wasko, U. N. et al. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature 629, 927\u2013936 (2024).","journal-title":"Nature"},{"key":"75960_CR14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","volume":"619","author":"D Kim","year":"2023","unstructured":"Kim, D. et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature 619, 160\u2013166 (2023).","journal-title":"Nature"},{"key":"75960_CR15","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature22341","volume":"546","author":"S Kamerkar","year":"2017","unstructured":"Kamerkar, S. et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546, 498\u2013503 (2017).","journal-title":"Nature"},{"key":"75960_CR16","doi-asserted-by":"publisher","unstructured":"Mendt, M. et al. Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.99263 (2018).","DOI":"10.1172\/jci.insight.99263"},{"key":"75960_CR17","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1158\/1078-0432.CCR-14-1591","volume":"21","author":"B Alagesan","year":"2015","unstructured":"Alagesan, B. et al. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clin. Cancer Res. 21, 396\u2013404 (2015).","journal-title":"Clin. Cancer Res."},{"key":"75960_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ccell.2015.11.011","volume":"29","author":"TK Hayes","year":"2016","unstructured":"Hayes, T. K. et al. Long-term ERK inhibition in KRAS-mutant pancreatic cancer is associated with MYC degradation and senescence-like growth suppression. Cancer Cell 29, 75\u201389 (2016).","journal-title":"Cancer Cell"},{"key":"75960_CR19","doi-asserted-by":"publisher","first-page":"e249840","DOI":"10.1001\/jamanetworkopen.2024.9840","volume":"7","author":"GT Moffat","year":"2024","unstructured":"Moffat, G. T. et al. KRAS allelic variants in biliary tract cancers. JAMA Netw. Open 7, e249840 (2024).","journal-title":"JAMA Netw. Open"},{"key":"75960_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1513\/pats.200809-107LC","volume":"6","author":"GJ Riely","year":"2009","unstructured":"Riely, G. J., Marks, J. & Pao, W. KRAS mutations in non-small cell lung cancer. Proc. Am. Thorac. Soc. 6, 201\u2013205 (2009).","journal-title":"Proc. Am. Thorac. Soc."},{"key":"75960_CR21","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1054\/bjoc.2001.1964","volume":"85","author":"HJ Andreyev","year":"2001","unstructured":"Andreyev, H. J. et al. Kirsten ras mutations in patients with colorectal cancer: the \u2018RASCAL II\u2019 study. Br. J. Cancer 85, 692\u2013696 (2001).","journal-title":"Br. J. Cancer"},{"key":"75960_CR22","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1158\/2159-8290.CD-20-0442","volume":"10","author":"MP Zafra","year":"2020","unstructured":"Zafra, M. P. et al. An in vivo kras allelic series reveals distinct phenotypes of common oncogenic variants. Cancer Discov. 10, 1654\u20131671 (2020).","journal-title":"Cancer Discov."},{"key":"75960_CR23","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.ccell.2024.08.002","volume":"42","author":"CA McIntyre","year":"2024","unstructured":"McIntyre, C. A. et al. Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer. Cancer Cell 42, 1614\u20131629 e1615 (2024).","journal-title":"Cancer Cell"},{"key":"75960_CR24","doi-asserted-by":"publisher","unstructured":"McAndrews, K. M. et al. CDK8 remodels the tumor microenvironment and promotes resistance to KRAS(G12D) inhibitors and daraxonrasib in PDAC. EMBO J. https:\/\/doi.org\/10.1038\/s44318-026-00854-5 (2026).","DOI":"10.1038\/s44318-026-00854-5"},{"key":"75960_CR25","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.1158\/0008-5472.CAN-23-2994","volume":"83","author":"AC Edwards","year":"2023","unstructured":"Edwards, A. C. et al. TEAD Inhibition Overcomes YAP1\/TAZ-driven primary and acquired resistance to KRASG12C inhibitors. Cancer Res. 83, 4112\u20134129 (2023).","journal-title":"Cancer Res."},{"key":"75960_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1158\/0008-5472.CAN-22-0391","volume":"83","author":"CM Goodwin","year":"2023","unstructured":"Goodwin, C. M. et al. Combination therapies with CDK4\/6 inhibitors to treat KRAS-mutant pancreatic cancer. Cancer Res. 83, 141\u2013157 (2023).","journal-title":"Cancer Res."},{"key":"75960_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cell.2014.06.003","volume":"158","author":"A Kapoor","year":"2014","unstructured":"Kapoor, A. et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 158, 185\u2013197 (2014).","journal-title":"Cell"},{"key":"75960_CR28","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371\u20132381 (2021).","journal-title":"N. Engl. J. Med."},{"key":"75960_CR29","doi-asserted-by":"publisher","first-page":"113911","DOI":"10.1016\/j.ejca.2024.113911","volume":"201","author":"JA Stratmann","year":"2024","unstructured":"Stratmann, J. A. et al. Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany. Eur. J. Cancer 201, 113911 (2024).","journal-title":"Eur. J. Cancer"},{"key":"75960_CR30","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.23.00434","volume":"41","author":"TS Bekaii-Saab","year":"2023","unstructured":"Bekaii-Saab, T. S. et al. Adagrasib in Advanced Solid Tumors Harboring a KRAS(G12C) Mutation. J. Clin. Oncol. 41, 4097\u20134106 (2023).","journal-title":"J. Clin. Oncol."},{"key":"75960_CR31","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","volume":"389","author":"MG Fakih","year":"2023","unstructured":"Fakih, M. G. et al. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N. Engl. J. Med. 389, 2125\u20132139 (2023).","journal-title":"N. Engl. J. Med."},{"key":"75960_CR32","doi-asserted-by":"publisher","first-page":"eabn4180","DOI":"10.1126\/science.abn4180","volume":"381","author":"X Lv","year":"2023","unstructured":"Lv, X. et al. Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors. Science 381, eabn4180 (2023).","journal-title":"Science"},{"key":"75960_CR33","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/2159-8290.CD-20-0142","volume":"11","author":"MH Hofmann","year":"2021","unstructured":"Hofmann, M. H. et al. BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. Cancer Discov. 11, 142\u2013157 (2021).","journal-title":"Cancer Discov."},{"key":"75960_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1158\/2159-8290.CD-22-0405","volume":"13","author":"R Yaeger","year":"2023","unstructured":"Yaeger, R. et al. Molecular characterization of acquired resistance to KRASG12C-EGFR inhibition in colorectal cancer. Cancer Discov. 13, 41\u201355 (2023).","journal-title":"Cancer Discov."},{"key":"75960_CR35","doi-asserted-by":"publisher","first-page":"4932","DOI":"10.1158\/1078-0432.CCR-24-1164","volume":"30","author":"H Singh","year":"2024","unstructured":"Singh, H. et al. Clinical and genomic features of classical and basal transcriptional subtypes in pancreatic cancer. Clin. Cancer Res. 30, 4932\u20134942 (2024).","journal-title":"Clin. Cancer Res."},{"key":"75960_CR36","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1158\/2159-8290.CD-24-0740","volume":"14","author":"A Singhal","year":"2024","unstructured":"Singhal, A. et al. A classical epithelial state drives acute resistance to KRAS inhibition in pancreatic cancer. Cancer Discov. 14, 2122\u20132134 (2024).","journal-title":"Cancer Discov."},{"key":"75960_CR37","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1158\/0008-5472.CAN-22-3050","volume":"83","author":"HL Williams","year":"2023","unstructured":"Williams, H. L. et al. Spatially resolved single-cell assessment of pancreatic cancer expression subtypes reveals co-expressor phenotypes and extensive intratumoral heterogeneity. Cancer Res. 83, 441\u2013455 (2023).","journal-title":"Cancer Res."},{"key":"75960_CR38","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","volume":"35","author":"W Liao","year":"2019","unstructured":"Liao, W. et al. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell 35, 559\u2013572.e557 (2019).","journal-title":"Cancer Cell"},{"key":"75960_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21736-w","volume":"12","author":"I Ischenko","year":"2021","unstructured":"Ischenko, I. et al. KRAS drives immune evasion in a genetic model of pancreatic cancer. Nat. Commun. 12, 1482 (2021).","journal-title":"Nat. Commun."},{"key":"75960_CR40","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.devcel.2023.07.025","volume":"58","author":"KK Mahadevan","year":"2023","unstructured":"Mahadevan, K. K. et al. Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8(+) T cells. Dev. Cell 58, 1562\u20131577.e1568 (2023).","journal-title":"Dev. Cell"},{"key":"75960_CR41","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","volume":"41","author":"KK Mahadevan","year":"2023","unstructured":"Mahadevan, K. K. et al. KRAS(G12D) inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8(+) T cells. Cancer Cell 41, 1606\u20131620.e1608 (2023).","journal-title":"Cancer Cell"},{"key":"75960_CR42","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.ccell.2022.07.005","volume":"40","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy. Cancer Cell 40, 1060\u20131069.e1067 (2022).","journal-title":"Cancer Cell"},{"key":"75960_CR43","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon, J. et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217\u2013223 (2019).","journal-title":"Nature"},{"key":"75960_CR44","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","volume":"378","author":"PM Forde","year":"2018","unstructured":"Forde, P. M. et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N. Engl. J. Med. 378, 1976\u20131986 (2018).","journal-title":"N. Engl. J. Med."},{"key":"75960_CR45","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1158\/0008-5472.CAN-17-3821","volume":"78","author":"AJ Rech","year":"2018","unstructured":"Rech, A. J. et al. Radiotherapy and CD40 activation separately augment immunity to checkpoint blockade in cancer. Cancer Res. 78, 4282\u20134291 (2018).","journal-title":"Cancer Res."},{"key":"75960_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32591-8","volume":"13","author":"DJ Renouf","year":"2022","unstructured":"Renouf, D. J. et al. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma. Nat. Commun. 13, 5020 (2022).","journal-title":"Nat. Commun."},{"key":"75960_CR47","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","volume":"170","author":"SC Wei","year":"2017","unstructured":"Wei, S. C. et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170, 1120\u20131133.e1117 (2017).","journal-title":"Cell"},{"key":"75960_CR48","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","volume":"581","author":"K Yamamoto","year":"2020","unstructured":"Yamamoto, K. et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature 581, 100\u2013105 (2020).","journal-title":"Nature"},{"key":"75960_CR49","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.4049\/jimmunol.181.5.3116","volume":"181","author":"TL Tinder","year":"2008","unstructured":"Tinder, T. L. et al. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J. Immunol. 181, 3116\u20133125 (2008).","journal-title":"J. Immunol."},{"key":"75960_CR50","doi-asserted-by":"publisher","unstructured":"Saraiva, M., Vieira, P. & O\u2019Garra, A. Biology and therapeutic potential of interleukin-10. J. Exp. Med. https:\/\/doi.org\/10.1084\/jem.20190418 (2020).","DOI":"10.1084\/jem.20190418"},{"key":"75960_CR51","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1136\/thx.51.2.143","volume":"51","author":"L Armstrong","year":"1996","unstructured":"Armstrong, L., Jordan, N. & Millar, A. Interleukin 10 (IL-10) regulation of tumour necrosis factor alpha (TNF-alpha) from human alveolar macrophages and peripheral blood monocytes. Thorax 51, 143\u2013149 (1996).","journal-title":"Thorax"},{"key":"75960_CR52","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.4049\/jimmunol.181.4.2277","volume":"181","author":"S Xiao","year":"2008","unstructured":"Xiao, S. et al. Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J. Immunol. 181, 2277\u20132284 (2008).","journal-title":"J. Immunol."},{"key":"75960_CR53","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fphar.2014.00080","volume":"5","author":"X Peng","year":"2014","unstructured":"Peng, X. et al. CD4+CD25+FoxP3+ regulatory Tregs inhibit fibrocyte recruitment and fibrosis via suppression of FGF-9 production in the TGF-beta1 exposed murine lung. Front Pharm. 5, 80 (2014).","journal-title":"Front Pharm."},{"key":"75960_CR54","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/nrc2761","volume":"9","author":"DW Kufe","year":"2009","unstructured":"Kufe, D. W. Mucins in cancer: function, prognosis and therapy. Nat. Rev. Cancer 9, 874\u2013885 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"75960_CR55","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","volume":"33","author":"RE Royal","year":"2010","unstructured":"Royal, R. E. et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 33, 828\u2013833 (2010).","journal-title":"J. Immunother."},{"key":"75960_CR56","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/CJI.0b013e31829fb7a2","volume":"36","author":"DT Le","year":"2013","unstructured":"Le, D. T. et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J. Immunother. 36, 382\u2013389 (2013).","journal-title":"J. Immunother."},{"key":"75960_CR57","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1158\/2326-6066.CIR-14-0215","volume":"3","author":"R Winograd","year":"2015","unstructured":"Winograd, R. et al. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunol. Res. 3, 399\u2013411 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"75960_CR58","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1158\/1078-0432.CCR-23-1444","volume":"30","author":"LR Ali","year":"2024","unstructured":"Ali, L. R. et al. PD-1 blockade induces reactivation of nonproductive T-cell responses characterized by NF-kappaB Signaling in Patients with Pancreatic Cancer. Clin. Cancer Res. 30, 542\u2013553 (2024).","journal-title":"Clin. Cancer Res."},{"key":"75960_CR59","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s12015-016-9670-8","volume":"12","author":"AM Ansari","year":"2016","unstructured":"Ansari, A. M. et al. Cellular GFP toxicity and immunogenicity: potential confounders in in vivo cell tracking experiments. Stem Cell Rev. Rep. 12, 553\u2013559 (2016).","journal-title":"Stem Cell Rev. Rep."},{"key":"75960_CR60","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1038\/sj.gt.3301335","volume":"7","author":"A Gambotto","year":"2000","unstructured":"Gambotto, A. et al. Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB\/c mice: identification of an H2-Kd-restricted CTL epitope. Gene Ther. 7, 2036\u20132040 (2000).","journal-title":"Gene Ther."},{"key":"75960_CR61","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1158\/1078-0432.CCR-18-0762","volume":"25","author":"A Sharma","year":"2019","unstructured":"Sharma, A. et al. Anti-CTLA-4 immunotherapy does not deplete FOXP3(+) regulatory T cells (Tregs) in human cancers. Clin. Cancer Res. 25, 1233\u20131238 (2019).","journal-title":"Clin. Cancer Res."},{"key":"75960_CR62","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"75960_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"75960_CR64","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1182\/blood-2007-09-115014","volume":"111","author":"SM Lee","year":"2008","unstructured":"Lee, S. M., Gao, B. & Fang, D. FoxP3 maintains Treg unresponsiveness by selectively inhibiting the promoter DNA-binding activity of AP-1. Blood 111, 3599\u20133606 (2008).","journal-title":"Blood"},{"key":"75960_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07735-4","volume":"9","author":"SI Koizumi","year":"2018","unstructured":"Koizumi, S. I. et al. JunB regulates homeostasis and suppressive functions of effector regulatory T cells. Nat. Commun. 9, 5344 (2018).","journal-title":"Nat. Commun."},{"key":"75960_CR66","doi-asserted-by":"publisher","unstructured":"Khor, B. et al. The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells. Elife. https:\/\/doi.org\/10.7554\/eLife.05920 (2015).","DOI":"10.7554\/eLife.05920"},{"key":"75960_CR67","doi-asserted-by":"publisher","first-page":"14942","DOI":"10.1073\/pnas.1520393112","volume":"112","author":"D Yan","year":"2015","unstructured":"Yan, D., Farache, J., Mingueneau, M., Mathis, D. & Benoist, C. Imbalanced signal transduction in regulatory T cells expressing the transcription factor FoxP3. Proc. Natl. Acad. Sci. USA 112, 14942\u201314947 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75960_CR68","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1182\/blood-2005-04-1632","volume":"106","author":"CA Wysocki","year":"2005","unstructured":"Wysocki, C. A. et al. Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood 106, 3300\u20133307 (2005).","journal-title":"Blood"},{"key":"75960_CR69","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.0105-2896.2006.00420.x","volume":"212","author":"MG Roncarolo","year":"2006","unstructured":"Roncarolo, M. G. et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 212, 28\u201350 (2006).","journal-title":"Immunol. Rev."},{"key":"75960_CR70","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1600-065X.2007.00565.x","volume":"220","author":"YY Wan","year":"2007","unstructured":"Wan, Y. Y. & Flavell, R. A. \u2018Yin-Yang\u2019 functions of transforming growth factor-beta and T regulatory cells in immune regulation. Immunol. Rev. 220, 199\u2013213 (2007).","journal-title":"Immunol. Rev."},{"key":"75960_CR71","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41590-019-0346-9","volume":"20","author":"DV Sawant","year":"2019","unstructured":"Sawant, D. V. et al. Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion. Nat. Immunol. 20, 724\u2013735 (2019).","journal-title":"Nat. Immunol."},{"key":"75960_CR72","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1182\/blood-2008-10-185223","volume":"113","author":"IA Parish","year":"2009","unstructured":"Parish, I. A. et al. The molecular signature of CD8+ T cells undergoing deletional tolerance. Blood 113, 4575\u20134585 (2009).","journal-title":"Blood"},{"key":"75960_CR73","doi-asserted-by":"publisher","first-page":"24392","DOI":"10.1073\/pnas.2007224117","volume":"117","author":"L Odagiu","year":"2020","unstructured":"Odagiu, L. et al. Early programming of CD8(+) T cell response by the orphan nuclear receptor NR4A3. Proc. Natl. Acad. Sci. USA 117, 24392\u201324402 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75960_CR74","doi-asserted-by":"publisher","first-page":"113898","DOI":"10.1016\/j.celrep.2024.113898","volume":"43","author":"T Srirat","year":"2024","unstructured":"Srirat, T. et al. NR4a1\/2 deletion promotes accumulation of TCF1(+) stem-like precursors of exhausted CD8(+) T cells in the tumor microenvironment. Cell Rep. 43, 113898 (2024).","journal-title":"Cell Rep."},{"key":"75960_CR75","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.18632\/aging.204486","volume":"15","author":"Y Duan","year":"2023","unstructured":"Duan, Y., Du, Y., Mu, Y., Gu, Z. & Wang, C. Expression, prognostic value and mechanism of SP100 family in pancreatic adenocarcinoma. Aging 15, 5569\u20135591 (2023).","journal-title":"Aging"},{"key":"75960_CR76","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1146\/annurev.immunol.20.100301.064807","volume":"20","author":"N Isakov","year":"2002","unstructured":"Isakov, N. & Altman, A. Protein kinase C(theta) in T cell activation. Annu Rev. Immunol. 20, 761\u2013794 (2002).","journal-title":"Annu Rev. Immunol."},{"key":"75960_CR77","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1002\/eji.200323996","volume":"33","author":"HW Lee","year":"2003","unstructured":"Lee, H. W., Nam, K. O., Park, S. J. & Kwon, B. S. 4-1BB enhances CD8+ T cell expansion by regulating cell cycle progression through changes in expression of cyclins D and E and cyclin-dependent kinase inhibitor p27kip1. Eur. J. Immunol. 33, 2133\u20132141 (2003).","journal-title":"Eur. J. Immunol."},{"key":"75960_CR78","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/j.ccell.2023.08.001","volume":"41","author":"G Escobar","year":"2023","unstructured":"Escobar, G. et al. Tumor immunogenicity dictates reliance on TCF1 in CD8(+) T cells for response to immunotherapy. Cancer Cell 41, 1662\u20131679.e1667 (2023).","journal-title":"Cancer Cell"},{"key":"75960_CR79","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/JLB.3A0218-071RRR","volume":"104","author":"CR Yu","year":"2018","unstructured":"Yu, C. R., Choi, J. K., Uche, A. N. & Egwuagu, C. E. Production of IL-35 by Bregs is mediated through binding of BATF-IRF-4-IRF-8 complex to il12a and ebi3 promoter elements. J. Leukoc. Biol. 104, 1147\u20131157 (2018).","journal-title":"J. Leukoc. Biol."},{"key":"75960_CR80","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Sautes-Fridman","year":"2019","unstructured":"Sautes-Fridman, C., Petitprez, F., Calderaro, J. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307\u2013325 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"75960_CR81","doi-asserted-by":"publisher","first-page":"eabf9419","DOI":"10.1126\/science.abf9419","volume":"375","author":"TN Schumacher","year":"2022","unstructured":"Schumacher, T. N. & Thommen, D. S. Tertiary lymphoid structures in cancer. Science 375, eabf9419 (2022).","journal-title":"Science"},{"key":"75960_CR82","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3389\/fimmu.2016.00407","volume":"7","author":"C Sautes-Fridman","year":"2016","unstructured":"Sautes-Fridman, C. et al. Tertiary lymphoid structures in cancers: prognostic value, regulation, and manipulation for therapeutic intervention. Front Immunol. 7, 407 (2016).","journal-title":"Front Immunol."},{"key":"75960_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers4010001","volume":"4","author":"F Bergomas","year":"2011","unstructured":"Bergomas, F. et al. Tertiary intratumor lymphoid tissue in colo-rectal cancer. Cancers 4, 1\u201310 (2011).","journal-title":"Cancers"},{"key":"75960_CR84","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1158\/1078-0432.CCR-13-2590","volume":"20","author":"G Di Caro","year":"2014","unstructured":"Di Caro, G. et al. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin. Cancer Res. 20, 2147\u20132158 (2014).","journal-title":"Clin. Cancer Res."},{"key":"75960_CR85","doi-asserted-by":"publisher","unstructured":"Evans, R. A. et al. Lack of immunoediting in murine pancreatic cancer reversed with neoantigen. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.88328 (2016).","DOI":"10.1172\/jci.insight.88328"},{"key":"75960_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40028-z","volume":"14","author":"M Zibelman","year":"2023","unstructured":"Zibelman, M. et al. A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors. Nat. Commun. 14, 4513 (2023).","journal-title":"Nat. Commun."},{"key":"75960_CR87","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","volume":"5","author":"EM O\u2019Reilly","year":"2019","unstructured":"O\u2019Reilly, E. M. et al. Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 5, 1431\u20131438 (2019).","journal-title":"JAMA Oncol."},{"key":"75960_CR88","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1128\/MCB.17.7.3850","volume":"17","author":"H Aktas","year":"1997","unstructured":"Aktas, H., Cai, H. & Cooper, G. M. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. Mol. Cell Biol. 17, 3850\u20133857 (1997).","journal-title":"Mol. Cell Biol."},{"key":"75960_CR89","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/emboj.2010.7","volume":"29","author":"M Drosten","year":"2010","unstructured":"Drosten, M. et al. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J. 29, 1091\u20131104 (2010).","journal-title":"EMBO J."},{"key":"75960_CR90","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1038\/sj.onc.1201105","volume":"14","author":"J Fan","year":"1997","unstructured":"Fan, J. & Bertino, J. R. K-ras modulates the cell cycle via both positive and negative regulatory pathways. Oncogene 14, 2595\u20132607 (1997).","journal-title":"Oncogene"},{"key":"75960_CR91","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/386177a0","volume":"386","author":"DS Peeper","year":"1997","unstructured":"Peeper, D. S. et al. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 386, 177\u2013181 (1997).","journal-title":"Nature"},{"key":"75960_CR92","doi-asserted-by":"publisher","unstructured":"Zhang, Y. et al. Epithelial-Myeloid cell crosstalk regulates acinar cell plasticity and pancreatic remodeling in mice. Elife. https:\/\/doi.org\/10.7554\/eLife.27388 (2017).","DOI":"10.7554\/eLife.27388"},{"key":"75960_CR93","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","volume":"21","author":"Y Pylayeva-Gupta","year":"2012","unstructured":"Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G. & Bar-Sagi, D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21, 836\u2013847 (2012).","journal-title":"Cancer Cell"},{"key":"75960_CR94","doi-asserted-by":"publisher","unstructured":"Gangaev, A. et al. Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response. Proc. Natl. Acad. Sci. USA. https:\/\/doi.org\/10.1073\/pnas.2102849118 (2021).","DOI":"10.1073\/pnas.2102849118"},{"key":"75960_CR95","doi-asserted-by":"crossref","unstructured":"Kvistborg, P. et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci. Transl. Med. 6, 254ra128 (2014).","DOI":"10.1126\/scitranslmed.3008918"},{"key":"75960_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60738-4","volume":"10","author":"C Friese","year":"2020","unstructured":"Friese, C. et al. CTLA-4 blockade boosts the expansion of tumor-reactive CD8(+) tumor-infiltrating lymphocytes in ovarian cancer. Sci. Rep. 10, 3914 (2020).","journal-title":"Sci. Rep."},{"key":"75960_CR97","doi-asserted-by":"publisher","unstructured":"Orlen, M. I. et al. T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDAC. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-1475 (2025).","DOI":"10.1158\/2159-8290.CD-24-1475"},{"key":"75960_CR98","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1158\/2159-8290.CD-24-0489","volume":"15","author":"Y Liu","year":"2025","unstructured":"Liu, Y. et al. Combined KRAS inhibition and immune therapy generates durable complete responses in an autochthonous PDAC model. Cancer Discov. 15, 162\u2013178 (2025).","journal-title":"Cancer Discov."},{"key":"75960_CR99","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1073\/pnas.1811067116","volume":"116","author":"J Blando","year":"2019","unstructured":"Blando, J. et al. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc. Natl. Acad. Sci. USA 116, 1692\u20131697 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"75960_CR100","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.ccr.2014.03.014","volume":"25","author":"F McAllister","year":"2014","unstructured":"McAllister, F. et al. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell 25, 621\u2013637 (2014).","journal-title":"Cancer Cell"},{"key":"75960_CR101","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1158\/2159-8290.CD-19-0297","volume":"10","author":"P Dey","year":"2020","unstructured":"Dey, P. et al. Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment. Cancer Discov. 10, 608\u2013625 (2020).","journal-title":"Cancer Discov."},{"key":"75960_CR102","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1158\/2326-6066.CIR-14-0016-T","volume":"2","author":"Y Zhang","year":"2014","unstructured":"Zhang, Y. et al. CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice. Cancer Immunol. Res. 2, 423\u2013435 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"75960_CR103","doi-asserted-by":"publisher","first-page":"101092","DOI":"10.1016\/j.xcrm.2023.101092","volume":"4","author":"H Lu","year":"2023","unstructured":"Lu, H. et al. Tumor and local lymphoid tissue interaction determines prognosis in high-grade serous ovarian cancer. Cell Rep. Med. 4, 101092 (2023).","journal-title":"Cell Rep. Med."},{"key":"75960_CR104","doi-asserted-by":"publisher","unstructured":"Amisaki, M. et al. IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer. Nature. https:\/\/doi.org\/10.1038\/s41586-024-08426-5 (2025).","DOI":"10.1038\/s41586-024-08426-5"},{"key":"75960_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-64980-y","volume":"14","author":"Y Weng","year":"2024","unstructured":"Weng, Y. et al. The impact of tertiary lymphoid structures on tumor prognosis and the immune microenvironment in non-small cell lung cancer. Sci. Rep. 14, 16246 (2024).","journal-title":"Sci. Rep."},{"key":"75960_CR106","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1172\/JCI71611","volume":"124","author":"NH Ruddle","year":"2014","unstructured":"Ruddle, N. H. Lymphatic vessels and tertiary lymphoid organs. J. Clin. Invest. 124, 953\u2013959 (2014).","journal-title":"J. Clin. Invest."},{"key":"75960_CR107","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.immuni.2011.10.015","volume":"35","author":"A Peters","year":"2011","unstructured":"Peters, A. et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 35, 986\u2013996 (2011).","journal-title":"Immunity"},{"key":"75960_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9280","volume":"6","author":"P Carrega","year":"2015","unstructured":"Carrega, P. et al. NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures. Nat. Commun. 6, 8280 (2015).","journal-title":"Nat. Commun."},{"key":"75960_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8114","volume":"6","author":"JD Peske","year":"2015","unstructured":"Peske, J. D. et al. Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nat. Commun. 6, 7114 (2015).","journal-title":"Nat. Commun."},{"key":"75960_CR110","doi-asserted-by":"publisher","first-page":"109422","DOI":"10.1016\/j.celrep.2021.109422","volume":"36","author":"AB Rodriguez","year":"2021","unstructured":"Rodriguez, A. B. et al. Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts. Cell Rep. 36, 109422 (2021).","journal-title":"Cell Rep."},{"key":"75960_CR111","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/j.1525-1594.2010.01113.x","volume":"34","author":"R McCoach","year":"2010","unstructured":"McCoach, R. et al. Pediatric extracorporeal life support systems: education and training at Penn State Hershey Children\u2019s Hospital. Artif. Organs 34, 1023\u20131026 (2010).","journal-title":"Artif. Organs"},{"key":"75960_CR112","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1158\/0008-5472.CAN-17-1987","volume":"78","author":"K Silina","year":"2018","unstructured":"Silina, K. et al. Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. Cancer Res. 78, 1308\u20131320 (2018).","journal-title":"Cancer Res."},{"key":"75960_CR113","doi-asserted-by":"publisher","first-page":"e1378844","DOI":"10.1080\/2162402X.2017.1378844","volume":"7","author":"F Posch","year":"2018","unstructured":"Posch, F. et al. Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. Oncoimmunology 7, e1378844 (2018).","journal-title":"Oncoimmunology"},{"key":"75960_CR114","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","volume":"7","author":"SR Hingorani","year":"2005","unstructured":"Hingorani, S. R. et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469\u2013483 (2005).","journal-title":"Cancer Cell"},{"key":"75960_CR115","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.ccell.2022.06.011","volume":"40","author":"Y Chen","year":"2022","unstructured":"Chen, Y. et al. Oncogenic collagen I homotrimers from cancer cells bind to alpha3beta1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. Cancer Cell 40, 818\u2013834.e819 (2022).","journal-title":"Cancer Cell"},{"key":"75960_CR116","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.cell.2018.05.061","volume":"174","author":"D van Dijk","year":"2018","unstructured":"van Dijk, D. et al. Recovering gene interactions from single-cell data using data diffusion. Cell 174, 716\u2013729.e727 (2018).","journal-title":"Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75960-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75960-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75960-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:02:58Z","timestamp":1787788978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-75960-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":116,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["75960"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-75960-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.M. is a consultant for Tezcat Biosciences and is named on a patent that has been licensed to Thrive Earlier Detection (an Exact Sciences company).\u00a0R.K., K.K.M., and MD Anderson have filed a patent application related to vaccination and combination treatment of pancreatic cancer. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9105"}}